Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05627245
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:29:04.620704+00:00
Published At
2026-04-22T00:00:00+00:00
Record Updated At
2026-04-22
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type", "Recurrent Follicular Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Recurrent T-Cell Non-Hodgkin Lymphoma", "Recurrent Transformed Non-Hodgkin Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type", "Refractory Follicular Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Refractory T-Cell Non-Hodgkin Lymphoma", "Refractory Transformed Non-Hodgkin Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-22"
protocolSection.identificationModule.nctId
"NCT05627245"
protocolSection.identificationModule.officialTitle
"Phase 1/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Recurrent B-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type (protocolSection.conditionsModule.conditions)
  • Recurrent Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent T-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Transformed Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory B-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type (protocolSection.conditionsModule.conditions)
  • Refractory Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory T-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Transformed Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.